Marker Therapeutics is trading 5.6% lower at $1.01; available company news identifies no new catalyst for October 1.
- Its latest listed press release, dated September 22, highlighted expanded manufacturing support from its CDMO partner.
- The broader market context is negative, but the provided major-index declines are each below 0.5%, so they do not establish a market-wide explanation.